The performance of Morgan Stanley’s MS trading business (constituting a significant portion of its top line) is expected to ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Morgan Stanley is a buy on weakness with strong dividend growth and projected revenue growth in Q4 2024 and early 2025. Click for our MS earnings preview.

Morgan Stanley expects improving freight conditions and upcoming emissions regulations to boost global truck manufacturers in ...

Wall Street’s largest investment banks are looking to award traders and dealmakers with their largest bonus increases since the pandemic, with ...

Global equity issuance rose 20% last year, but stock market launches have so far lagged that increase, remaining far below ...

The Goldman Sachs Group, Inc. GS is scheduled to release fourth-quarter 2024 earnings on Jan. 15 before the opening bell. Goldman’s close peer JP Morgan JPM is slated to announce quarterly numbers on ...

Andrew Forrest has taken a ‘bring it on’ stance in response to ExxonMobil’s defamation lawsuit, which it has filed against ...

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 ...

(Reuters) - Top Wall-Street brokerages revised their Fed rate cut forecasts, after a blow-out U.S. jobs report on Friday, ...

British equities slipped on Friday, with financial sectors such as insurance and lenders leading losses ahead of the U.S.